Page 33 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine FAP-targeted RLT in cancer

https://doi.org/10.1097/RLU.0000000000003678 https://doi.org/10.1056/NEJMoa1507643
44. Assadi M, Rekabpour SJ, Jafari E, et al., 2021, Feasibility and 54. Schoenfeld AJ, Hellmann MD, 2020, Acquired resistance to
therapeutic potential of 177 Lu-fibroblast activation protein immune checkpoint inhibitors. Cancer Cell, 37: 443–455.
inhibitor-46 for patients with relapsed or refractory cancers: https://doi.org/10.1016/j.ccell.2020.03.017
A preliminary study. Clin Nucl Med, 46: e523–e530.
55. Joyce JA, Fearon DT, 2015, T cell exclusion, immune
https://doi.org/10.1097/RLU.0000000000003810 privilege, and the tumor microenvironment. Science,
45. Ballal S, Yadav MP, Moon ES, et al., 2021, First-in-human results 348: 74–80.
on the biodistribution, pharmacokinetics, and dosimetry of https://doi.org/10.1126/science.aaa6204
[177 Lu Lu-DOTA.SA.FAPi and [ Lu]Lu-DOTAGA.(SA.FAPi)
]
177
(2). Pharmaceuticals (Basel), 14: 1212. 56. Sahai E, Astsaturov I, Cukierman E, et al., 2020, A framework
for advancing our understanding of cancer-associated
https://doi.org/10.3390/ph14121212 fibroblasts. Nat Rev Cancer, 20: 174–186.
46. Kuyumcu S, Kovan B, Sanli Y, et al., 2021, Safety of fibroblast https://doi.org/10.1038/s41568-019-0238-1
activation protein-targeted radionuclide therapy by a low-
dose dosimetric approach using 177 Lu-FAPI04. Clin Nucl 57. Grout JA, Sirven P, Leader AM, et al., 2022, Spatial
Med, 46: 641–646. positioning and matrix programs of cancer-associated
fibroblasts promote T-cell exclusion in human lung tumors.
https://doi.org/10.1097/RLU.0000000000003667 Cancer Discov, 12: 2606–2625.
47. Baum RP, Schuchardt C, Singh A, et al., 2022, Feasibility, https://doi.org/10.1158/2159-8290.CD-21-1714
biodistribution, and preliminary dosimetry in peptide-
targeted radionuclide therapy of diverse adenocarcinomas 58. Dearnaley DP, Jovic G, Syndikus I, et al., 2014, Escalated-
dose versus control-dose conformal radiotherapy for
177
using Lu-FAP-2286: First-in-humans results. J Nucl Med, prostate cancer: Long-term results from the MRC RT01
63: 415–423.
randomised controlled trial. Lancet Oncol, 15: 464–473.
https://doi.org/10.2967/jnumed.120.259192
https://doi.org/10.1016/S1470-2045(14)70040-3
48. Ferdinandus J, Costa PF, Kessler L, et al., 2022, Initial
clinical experience with Y-FAPI-46 radioligand therapy 59. Hall S, Rudrawar S, Zunk M, et al., 2016, Protection against
90
radiotherapy-induced toxicity. Antioxidants (Basel), 5: 22.
for advanced-stage solid tumors: A case series of 9 patients.
J Nucl Med, 63: 727–734. https://doi.org/10.3390/antiox5030022
https://doi.org/10.2967/jnumed.121.262468 60. Jagodinsky JC, Jin WJ, Bates AM, et al., 2021, Temporal
analysis of Type 1 interferon activation in tumor cells
49. Fendler WP, Pabst KM, Kessler L, et al., 2022, Safety and following external beam radiotherapy or targeted
efficacy of 90Y-FAPI-46 radioligand therapy in patients with radionuclide therapy. Theranostics, 11: 6120–6137.
advanced sarcoma and other cancer entities. Clin Cancer
Res, 28: 4346–4353. https://doi.org/10.7150/thno.54881
https://doi.org/10.1158/1078-0432.CCR-22-1432 61. Patel RB, Hernandez R, Carlson P, et al., 2021, Low-dose
targeted radionuclide therapy renders immunologically
50. Kaghazchi F, Aghdam RA, Haghighi S, et al., 2022, cold tumors responsive to immune checkpoint blockade. Sci
177 Lu-FAPI therapy in a patient with end-stage metastatic Transl Med, 13: eabb3631.
pancreatic adenocarcinoma. Clin Nucl Med, 47: e243–e245.
https://doi.org/10.1126/scitranslmed.abb3631
https://doi.org/10.1097/RLU.0000000000004021
90
62. Hernandez R, Walker KL, Grudzinski JJ, et al., 2019, Y-
51. Ballal S, Yadav MP, Moon ES, et al., 2022, Novel fibroblast NM600 targeted radionuclide therapy induces immunologic
activation protein inhibitor-based targeted theranostics memory in syngeneic models of T-cell non-Hodgkin’s
for radioiodine-refractory differentiated thyroid cancer lymphoma. Commun Biol, 2: 79.
patients: A pilot study. Thyroid, 32: 65–77.
https://doi.org/10.1038/s42003-019-0327-4
https://doi.org/10.1089/thy.2021.0412
63. Twyman-Saint Victor C, Rech AJ, Maity A, et al., 2015,
52. Darvin P, Toor SM, Sasidharan Nair V, et al., 2018, Immune Radiation and dual checkpoint blockade activate non-
checkpoint inhibitors: Recent progress and potential redundant immune mechanisms in cancer. Nature,
biomarkers. Exp Mol Med, 50: 1–11. 520: 373–377.
https://doi.org/10.1038/s12276-018-0191-1 https://doi.org/10.1038/nature14292
53. Borghaei H, Paz-Ares L, Horn L, et al., 2015, Nivolumab 64. Thierens HM, Monsieurs MA, Brans B, et al., 2001,
versus docetaxel in advanced nonsquamous non-small-cell Dosimetry from organ to cellular dimensions. Comput Med
lung cancer. N Engl J Med, 373: 1627–1639. Imaging Graph, 25: 187–193.

Volume 1 Issue 2 (2023) 12 https://doi.org/10.36922/arnm.1667